Prostate Cancer Diagnostics

ASCO Releases New Recommendations on Germline and Somatic Testing for Metastatic PCa

New recommendations released by the American Society of Clinical Oncology (ASCO) have provided updates to guidelines on the use of germline and somatic genomic testing for patients with metastatic prostate cancer (PCa). A systematic review utilized articles from the PubMed database that were searched from January 2018 to May 2024. The review involved a multidisciplinary panel with patient representation. ...

Latest News

Precision Medicine in Prostate Cancer: A Multidisciplinary Discussion

Jacob Ark, MDCRPC | February 3, 2025

Expert panel discusses diagnostic criteria, precision medicine, and PSMA imaging in managing metastatic prostate cancer.

Clarity Pharmaceuticals Receives FDA Fast Track Designation for Cu-64 SAR-bisPSMA Prostate Cancer Imaging Agent

Brandon TwyfordProstate Cancer Diagnostics | January 24, 2025

The FDA's Fast Track Designation enables expedited development of 64Cu-SAR-bisPSMA for recurrent prostate cancer imaging.

PSMA PET Utility for Determining Optimal Candidates for Focal Therapy

Rafael Sanchez-Salas, MDLocalized | January 21, 2025

Dr. Sanchez-Salas comments on whether PSMA PET is useful for determining optimal candidates for focal therapy.

BCR Treatment With Focal Therapy: PSMA PET and Salvage Prostatectomy

Jihad Kaouk, MDLocalized | January 21, 2025

Dr. Kaouk presented on the benefits of surgery for managing biochemically recurrent prostate cancer post-radiation.

Long-Term Complications of Prostate Cancer Treatment: PSA Testing

Ian Thompson, Jr., MDLocalized | January 21, 2025

Dr. Thompson, Jr. highlights his recently published large dataset of long-term complications of prostate cancer treatment.

PSMA-PET vs Conventional Imaging: A Post Hoc Analysis of EMBARK Patients With nmHSPC

Emily MenendezmHSPC | January 15, 2025

Conventional imaging may understage patients with HR nmHSPC compared to PSMA-PET imaging.

Prostate Cancer Knowledge Hubs

Curated clinical content on prostate cancer types, therapies, and technologies

Prostate Cancer

Localized

nmCRPC

CRPC

mHSPC

RLT

Prostate Cancer

Localized

nmCRPC

CRPC

Conference Coverage

ADAPT-BLADDER Cohort 4: A Phase 1/2 Trial of Durvalumab Plus Intravesical Gemcitabine and Docetaxel in BCG-Unresponsive NMIBC

Noah Hahn, MDUrothelial Carcinoma | February 24, 2025

Noah Hahn, MD, gives an overview of durvalumab with intravesical gemcitabine and docetaxel for BCG-unresponsive NMIBC.

Extensive Necrosis as a Prognostic Indicator in mRCC Treated With Deferred Cytoreductive Nephrectomy After ICI Treatment

Daniel Joyce, MDRenal Cell Carcinoma | February 24, 2025

Dr. Daniel Joyce gives an overview of his study that examined the use of necrosis as a prognostic indicator for mRCC.

ASCO GU Prostate Updates: TALAPRO-2 and Other Considerations

Karine Tawagi, MDProstate Cancer | February 24, 2025

Drs. Karine Tawagi and Samantha Armstrong expand on the prostate cancer discussions of note, including TALAPRO-2.

ASCO GU Bladder Updates: EV-302, CheckMate 274, and More

Karine Tawagi, MDUrothelial Carcinoma | February 24, 2025

Drs. Tawagi and Armstrong provide detail and discussion on the bladder cancer research from the 2025 ASCO GU meeting.

ASCO GU Kidney Updates: Triplets, KIM-1, and More

Karine Tawagi, MDRenal Cell Carcinoma | February 24, 2025

Drs. Tawagi and Armstrong recap the hottest topics in kidney cancer research from the 2025 ASCO GU Cancers Symposium.

EV-302: Updated Analysis From the Phase 3 Global Study

Guru P. Sonpavde, MDUrothelial Carcinoma | February 24, 2025

Dr. Sonpavde provides an update on the latest analysis from the phase 3 global study of EV in combination with pembro.